It’s where the disconnect is, between the market and the industry itself.
But I agree on the first 2 points in terms of failure of management to fund earlier at a higher pps, and overall poor marketing.
They don’t need a new product.
The one they have, Algovita, is excellent. But again, poor marketing to fail to plant themselves where they should be.
They have $70 million roughly in cash, so I’m not worried about the full dilution in terms of shares, as I feel they will wait until prices recover to sell much. But I could be wrong.
And I still think it’s been a mix of allowing and forcing it down. I don’t think retail has played much of a roll in the rise OR decline.
Either way, I think all your points and concern are fairly valid, C.
Even the best team that money can buy fails to make the playoffs....
